Selective serotonin reuptake inhibitors (SSRIs) including sertraline have been found to be effective in the treatment of generalized social phobia (GSP). However, virtually all of the current treatment studies with medicines, including the SSRIs, have excluded patients with social phobia who have other co-occurring conditions. In fact, 80% of individuals suffering with primary social phobia have at least one other anxiety. This study will evaluate the safety and efficacy of sertraline in the treatment of generalized social phobia with co-occurring anxiety and mood disorders.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
170
25 - 200 mg/day x 16 weeks
25 - 200 mg/day x 16 weeks
MacAnxiety Research Centre
Hamilton, Ontario, Canada
Clinical Global Impression - Improvement ≤ 2
Time frame: 16 weeks
Liebowitz Social Anxiety Scale [LSAS] (mean change from baseline)
Time frame: 16 weeks
Mean change from baseline on the following scales: Quality of Life and Employment Satisfaction Questionnaire
Time frame: 16 weeks
Sheehan Disability Scale
Time frame: 16 weeks
Social Phobia Scale
Time frame: 16 weeks
Brief Social Phobia Scale
Time frame: 16 weeks
Penn State Worry Questionnaire
Time frame: 16 weeks
Panic and Agoraphobia Scale
Time frame: 16 weeks
Davidson Trauma Scale
Time frame: 16 weeks
Social Anxiety Spectrum Self-Report (SHY-SR)
Time frame: 16 weeks
Yale-Brown Obsessive Compulsive Scale
Time frame: 16 weeks
Montgomery-Asberg Depression Rating Scale (MADRS)
Time frame: 16 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.